Results 151 to 160 of about 31,766 (260)

Pharmacovigilance analysis of cutaneous adverse drug reactions for cetuximab, panitumumab, and necitumumab based on EudraVigilance and WHO VigiAccess. [PDF]

Front Pharmacol
Sauer N, Giedziun P, Calik J, Wiela-Hojeńska A.   +3 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Mental Health Disorders in Type 2 Diabetes: Active Comparator, New User Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims We evaluated the risk of mental health disorders among glucagon‐like peptide‐1 receptor agonist (GLP1RA) users compared with users of dipeptidyl peptidase‐4 (DPP‐4) inhibitors and sodium‐glucose cotransporter‐2 (SGLT2) inhibitors. Materials and Methods We conducted a nationwide, active‐comparator new‐user cohort study using the Korean ...
Chungsoo Kim, Seonji Kim, Dong Yun Lee, Eugene Han, Yong‐ho Lee, Seng Chan You   +5 more
wiley   +1 more source

Estriol Is Likely Not Associated With Mouth Ulcerations in Pharmacovigilance Data. [PDF]

Int Dent J
Böhm R, Herdegen T.
europepmc   +1 more source

GLP‐1 Receptor Agonists and Risk of Skin Cancer in Adults With Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Existing evidence regarding the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and risk of melanoma and non‐melanoma skin cancer (NMSC) is inconclusive. This study aimed to assess the association between GLP‐1RA initiation and risks of melanoma and NMSC versus sodium–glucose cotransporter 2 inhibitors (SGLT2is ...
Huilin Tang, Bingyu Zhang, Ying Lu, Ting Zhou, Yiwen Lu, César A. Briceño, Jiali Han, Yong Chen   +7 more
wiley   +1 more source

Phase IIB, Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial of Intravenous Defibrotide for the Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome in COVID‐19

European Journal of Haematology, EarlyView.
ABSTRACT Introduction Endothelial dysfunction is key in COVID‐19 pathogenesis. This randomized, double‐blind phase IIb trial investigated continuous intravenous infusion of defibrotide in patients hospitalized with SARS‐CoV‐2 infection and respiratory failure.
Ruben Jara Rubio, Antonio José Martinez‐Mellado, Jonathan Kiwitt‐Cárdenas, José G. Clavel, Bartolomé García‐Perez, Pedro Castro, Maribel Diaz‐Ricart, Andrés Carrillo‐Alcaraz, Amparo López‐Bernús, Enrique Bernal Morell, Aychel Roura, Sonia Marín, Francisco‐José Ruiz‐López, Elena Solana‐Martinez, Domingo Martinez‐Baño, Carlos L. Albacete Moreno, Enriqueta Andreu Soler, Adrián Tellez Santoyo, Sara Fernández Méndez, Jose A. Noguera Velasco, Iria Cebreiros Lopez, Andrés Parrilla, Alberto Espuny‐Miró, David García‐Bernal, Miguel Blanquer, Andrés Sánchez‐Salinas, Francisca Iniesta, Cristina Hernandez Garcia, Manuel Muro, Alfredo Minguela Puras, Antonio Moreno‐Docón, Alberto M. Torres‐Cantero, Maria Munoz Garcia, Manuel Serrano, Massimo Iacobelli, Carmelo Carlo‐Stella, Lee‐Jen Wei, Paul G. Richardson, José M. Moraleda   +38 more
wiley   +1 more source

Absence of pharmacovigilance signals for bleeding events associated with warfarin-SSRI drug interactions: a comparative analysis of FAERS and CVARD databases. [PDF]

Ther Adv Drug Saf
Zhang P, Cheng S, Diao J, Zhu H.
europepmc   +1 more source

Migraine, monoclonal antibodies, and monitoring: a review of pharmacovigilance in the era of biologics. [PDF]

Front Pharmacol
Guarnieri L, Bosco F, Corasaniti MT, Citraro R, De Sarro G.   +4 more
europepmc   +1 more source

Bringing Gene Therapy Into Real World Clinical Practice

Haemophilia, EarlyView.
ABSTRACT Introduction Adeno‐associated virus (AAV)‐based gene therapy for haemophilia has shifted therapeutic paradigms by enabling hepatic gene transfer, restoring endogenous clotting factor expression, and reducing reliance on conventional prophylactic treatments. Two products, valoctocogene roxaparvovec (haemophilia A) and etranacogene dezaparvovec (
Wolfgang Miesbach, Pratima Chowdary, Margareth C. Ozelo   +2 more
wiley   +1 more source

Performance of active drug safety monitoring and management for pharmacovigilance strengthening in Ethiopia, experience from a multidrug-resistant tuberculosis management program: a cross-sectional study. [PDF]

BMJ Open
Achalu DL, Meshesha SG, Kiltu AB, Wendimu DE, Tegegne NA, Alemu A, Tiemersma EW, Cobelens F, Teferi M.   +8 more
europepmc   +1 more source

Potential association of cluster headache with certain COVID‐19 vaccines: An assessment from the pharmacovigilance databases

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background The main objective of our study was to assess the potential association between coronavirus disease 2019 (COVID‐19) vaccination and cluster headache (CH) using a pharmacovigilance approach. A secondary objective was to determine whether COVID‐19 vaccines predominantly triggered onset or worsening of the disease.
Elise K. Van Obberghen, Laura Parigny, Nouha Ben‐Othman, Elliot Ewig, Milou‐Daniel Drici, Alexandre O. Gérard, Sophie Gautier, Michel Lanteri‐Minet   +7 more
wiley   +1 more source